Table 1.
Baseline characteristics of hepatocellular carcinoma patients after curative hepatectomy
| Characteristics | Total (n=240) | Survival group (n=135) | P valueΔ | Recurrence group (n=150) | P value▲ |
|---|---|---|---|---|---|
| Male, n (%) | 199 (82.9) | 110 (81.5) | 0.503 | 121 (80.7) | 0.232 |
| Age, median (IQR), years | 53 (45-61) | 53 (45-60) | 0.698 | 52 (44-60) | 0.031 |
| Etiology, n (%) | 0.302 | 0.002 | |||
| HBV infection | 186 (77.5) | 108 (80.0) | 126 (84.0) | ||
| HCV infection | 20 (8.3) | 8 (5.9) | 12 (8.0) | ||
| Other | 34 (14.2) | 19 (14.1) | 12 (8.0) | ||
| Tumor size, median (IQR), cm | 3.7 (2.5-6.15) | 3.2 (2.2-5.0) | <0.001 | 3.95 (2.7-7.05) | 0.029 |
| Liver histology of non-tumor | 0.352 | 0.01 | |||
| Cirrhosis | 115 (47.9) | 57 (42.2) | 84 (56.0) | ||
| Chronic active hepatitis | 58 (24.2) | 36 (26.7) | 37 (24.7) | ||
| Chronic persistent hepatitis | 36 (15.0) | 23 (17.0) | 20 (13.3) | ||
| Reactive hepatitis | 11 (4.6) | 5 (3.7) | 5 (3.3) | ||
| Alcoholic hepatitis | 11 (4.6) | 7 (5.2) | 3 (2.0) | ||
| Vascular invasion, n (%) | 133 (55.4) | 60 (44.4) | <0.001 | 96 (64.0) | 0.001 |
| Major portal vein invasion, n (%) | 9 (3.8) | 1 (0.7) | 0.011 | 8 (5.3) | 0.159 |
| Intrahepatic metastasis, n (%) | 55 (22.9) | 13 (9.6) | <0.001 | 50 (33.3) | <0.001 |
| Multicentric occurrence, n (%) | 13 (5.4) | 7 (5.2) | 0.857 | 8 (5.3) | 0.941 |
| Direct invasion of adjacent organ, n (%) | 5 (2.1) | 2 (1.5) | 0.656 | 4 (2.7) | 0.653 |
| AJCC stage, n (%) | <0.001 | <0.001 | |||
| I | 102 (42.5) | 73 (54.1) | 52 (34.7) | ||
| II | 100 (41.7) | 53 (39.3) | 64 (42.7) | ||
| III | 33 (13.8) | 7 (5.2) | 30 (20.0) | ||
| IV | 5 (2.1) | 2 (1.5) | 4 (2.7) | ||
| BCLC stage, n (%) | <0.001 | 0.012 | |||
| A | 139 (57.9) | 96 (71.1) | 76 (50.7) | ||
| B | 91 (37.9) | 37 (27.4) | 66 (44.0) | ||
| C | 10 (4.2) | 2 (1.5) | 8 (5.3) | ||
| Alpha-fetoprotein >200 ng/ml, n (%) | 87 (36.3) | 45 (33.3) | 0.287 | 63 (42.0) | 0.017 |
| BMI, mean ± SD, kg/m2 | 24.2±2.8 | 24.6±2.9 | 0.009 | 24.0±2.7 | 0.234 |
Δ
compared to death patients;
▲
compared to patient without recurrence.